TargetBeta
PTK7
protein tyrosine kinase 7 (inactive) · also CCK4 · I-set domain containing
5 programs in company-led studies act on PTK7, from 5 companies: 0 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (5 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Anti-PTK7 Antibody-drug Conjugate SKB518rule | Sichuan Kelun Pharmaceutical | phase 2 | 33 running | – | NCIt |
| Anti-B7-H3/Anti-PTK7-TOP1i Bispecific Antibody-drug Conjugate IDE034rule | IDEAYA Biosciences | phase 1 | 11 running | CD276 | NCIt |
| Anti-PTK7 Antibody-drug Conjugate HWK-007rule | Whitehawk Therapeutics | phase 1 | 11 running | – | NCIt |
| Anti-PTK7/Exatecan Antibody-drug Conjugate DAY301rule | Day One Biopharmaceuticals | phase 1 | 11 running | – | NCIt |
| Anti-PTK7/Exatecan Antibody-drug Conjugate LY4175408rule | Eli Lilly | phase 1 | 11 running | – | NCIt |
Also acted on by the same programs
Conditions their studies are in
- Carcinoma, Non-Small-Cell Lung, 1 program
- Endometrial Neoplasms, 1 program
- Esophageal Squamous Cell Carcinoma, 1 program
- Lung Neoplasms, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Feb 20, 2027Anti-PTK7 Antibody-drug Conjugate SKB518 · Sichuan Kelun Pharmaceutical · phase 2 · NCT07019675
- Jul 30, 2027Anti-B7-H3/Anti-PTK7-TOP1i Bispecific Antibody-drug Conjugate IDE034 · IDEAYA Biosciences · phase 1 · NCT07503808
- Dec 2027Anti-PTK7/Exatecan Antibody-drug Conjugate DAY301 · Day One Biopharmaceuticals · phase 1 · NCT06752681
- Oct 2028Anti-PTK7 Antibody-drug Conjugate HWK-007 · Whitehawk Therapeutics · phase 1 · NCT07444814
- Jul 2030Anti-PTK7/Exatecan Antibody-drug Conjugate LY4175408 · Eli Lilly · phase 1 · NCT07046923
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.